Diane A. Blake, Ph.D.
Professor of Biochemisty
Tulane Cancer Center Contributing Member
Address: 1430 Tulane Ave., Box SL-43, New Orleans, LA 70112-2699
Dr. Blake received her B.S. in Biochemistry in 1972 from Ohio State University in Columbus, Ohio. She then moved to the University of Illinois at Urbana-Champaign to study proteoglycan biosynthesis/structure with H. Edward Conrad and received her PhD in Biochemistry in 1977. After a 4-year postdoctoral fellowship studying lectin biochemistry and glycoprotein synthesis with Irwin J. Goldstein at the University of Michigan, Ann Arbor, MI, she joined Miles Laboratories as a Research Scientist in 1981. In 1983 she took a faculty position at Meharry Medical College in Nashville, TN, where she remained for 9 years. She came to Tulane in 1993 and is now Professor of Biochemistry. Dr. Blake has published over 50 papers in the areas of glycoprotein/proteoglycan biochemistry and protein-ligand interactions. She served for 5 years as a Member of the Advisory Panel for Cell Biology for the National Science Foundation and recently was a Panel Member for their Biocomplexity initiative. She has also served on Review Panels of the Environmental Protection Agency and performed ad hoc reviews for the National Institutes of Health, the Wellcome Trust (UK), and the North Carolina Biotechnology Center. She reviews regularly for Investigative Ophthalmology and Visual Sciences and Analytica Chemistry. One area of Dr. Blake's research is focused upon a study of extracellular matrix and cell-matrix interactions. Her most recent projects have included signal transduction via extracellular matrix receptors, and research on the effects of extracellular molecules on cell migration and proliferation. She has concentrated upon those extracellular matrix molecules that influence the behavior of vascular endothelial cells. A practical outcome of her experiments has been the development of new drugs (based on extracellular matrix molecules) that inhibit the process of angiogenesis. Such angiogenesis inhibitors have applications in the control of both cancer and ocular disease. A second area of active research in Blake's laboratory is the development of antibody reagents that can be used to assess human exposure to heavy metals. Some of the antibodies she has developed for this project also have applications in cancer prognosis and therapy.
Blake II RC, Pavlov AR, Blake DA. Automated kinetic exclusion assays to quantify protein binding interactions in homogeneous solution. Anal Biochem 272:123-134 (1999)
Shafiee A, Penn JS, Krutzsch HC, Inman JK, Roberts DD, and Blake DA. Inhibition of retinal angiogenesis by peptides derived from thrombospondin-1. Invest Ophthalmol Vis Sci 41:2378-2388 (2000)
Muhitch JW, O'Connor KC, Blake DA, Lacks DJ, Rosenzweig N, Spaulding GF. Characterization of aggregation and protein expression of bovine corneal endothelial cells as microcarrier cultures in a rotating-wall vessel. Cytotechnol 32:253-263 (2000)
Darwish IA , Blake DA. Development and validation of a sensitive one-step immunoassay for determination of cadmium in human serum. Anal Chem 74:52-58 (2002)
Blake II RC, JDelehanty JB, Khosraviani M, Yu H, Jones RM, Blake DA. Allosteric binding properties of a monoclonal antibody and its Fab fragment. Biochemistry 42:497-598 (2003)
Blake II RC, Pavlov AR, Khosraviani M, Ensley HE, Kiefer GE, Yu H, Li X, Blake DA. Novel monoclonal antibodies with specificity for chelated uranium(VI): Isolation and binding properties. Bioconjugate Chemistry 15:1125-1136 (2004)
Glass TR, Ohmura N, Saiki H, Blake DA, Blake II RC, Lackie SJ. Use of excess solid phase capacity in immunoassays: Advantages for semi-continuous, near real time measurements and for analysis of matrix effects. Anal Chem 76:767-772 (2004)